Clinical Trial Update: Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating QVM149 as a bronchodilator in asthma, comparing morning vs evening dosing to placebo, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QVM149 (Indacaterol acetate / glycopyrronium bromide / mometasone furoate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-21